NovaPoint Capital LLC Sells 155 Shares of Zoetis Inc. (NYSE:ZTS)

NovaPoint Capital LLC lowered its position in Zoetis Inc. (NYSE:ZTS) by 3.8% in the 4th quarter, Holdings Channel reports. The fund owned 3,977 shares of the company’s stock after selling 155 shares during the quarter. NovaPoint Capital LLC’s holdings in Zoetis were worth $648,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Darwin Wealth Management LLC bought a new position in shares of Zoetis in the 3rd quarter worth approximately $31,000. First Personal Financial Services bought a new position in Zoetis during the 3rd quarter valued at approximately $33,000. Capital Performance Advisors LLP bought a new position in Zoetis during the 3rd quarter valued at approximately $33,000. Dunhill Financial LLC increased its position in Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after buying an additional 75 shares in the last quarter. Finally, Fortitude Family Office LLC increased its position in Zoetis by 1,387.5% during the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock valued at $46,000 after buying an additional 222 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

NYSE:ZTS opened at $175.65 on Thursday. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The business’s 50-day simple moving average is $169.41 and its two-hundred day simple moving average is $179.35. The stock has a market cap of $79.25 billion, a PE ratio of 33.02, a P/E/G ratio of 2.72 and a beta of 0.90. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business’s quarterly revenue was up 11.6% on a year-over-year basis. During the same period last year, the firm earned $1.36 earnings per share. As a group, analysts forecast that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Tuesday, January 21st. This is a boost from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 dividend on an annualized basis and a yield of 1.14%. Zoetis’s dividend payout ratio (DPR) is currently 37.59%.

Analyst Upgrades and Downgrades

ZTS has been the topic of several recent analyst reports. Morgan Stanley cut their target price on Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. UBS Group initiated coverage on Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 target price on the stock. JPMorgan Chase & Co. increased their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Leerink Partners assumed coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Zoetis currently has a consensus rating of “Buy” and a consensus target price of $215.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.